Filibuvir (PF00868554; PF-00868554) is a novel and potent NS5B inhibitor of the non-nucleoside inhibitor (NNI) class developed for the treatment of hepatitis C. It inhibits the HCV nonstructural 5B protein (NS5B) RNA-dependent RNA polymerase, by binding noncovalently in the non-catalytic “Thumb 2” allosteric pocket of NS5B and causes a decrease in viral RNA synthesis. In vitro, filibuvir is equipotent against genotype 1a and 1b replicons, with an EC50 of 59 nM.

纯度：≥98%

CAS：877130-28-4